Completed PHASE2 INTERVENTIONAL 1-arm NCT00039494

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme

Sponsor: National Cancer Institute (NCI)

Conditions Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma

Interventions 3-dimensional conformal radiation therapy erlotinib hydrochloride temozolomide

Updated 6 times since 2017 Last updated: Aug 1, 2013 Started: Dec 31, 2002 Primary completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00039494, this PHASE2 trial focuses on Adult Giant Cell Glioblastoma and Adult Glioblastoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States , Ames, United States , Ann Arbor, United States , Anthony, United States , Athens, United States , Aurora, United States , Bemidji, United States , Bettendorf, United States , Billings, United States , Bismarck, United States and 75 more locations